

Hamilton Medical Press Release / 10.07.2023

Hamilton Medical obtains final favorable decision at the U.S. Court of Appeals for the Federal Circuit clearing the way for pending FDA approval of INTELLiVENT[®]-ASV[®]

Hamilton Medical AG (together with other Hamilton companies including Hamilton Technologies LLC, hereinafter referred to collectively as Hamilton) obtained a final favorable decision from the U.S. Court of Appeals for the Federal Circuit on June 28, 2023.

The U.S. Court of Appeals for the Federal Circuit affirmed a previous decision made in Hamilton's favor by the U.S. Patent and Trademark Office Patent Trial and Appeal Board in 2021.

The case arose from assertions of patent infringement made by Dr. Fleur Tehrani. The Federal Circuit ultimately held the challenged claims of the asserted patent to be invalid, clearing the way for Hamilton to proceed with pending FDA approval of its INTELLiVENT[®]-ASV[®] control system.


The Federal Circuit's decision also aligns with a final decision in favor of Hamilton handed down by the United Kingdom's Intellectual Property Enterprise Court in 2022.

Hamilton remains committed to providing safe, effective, and lung-protective ventilation to patients all over the world and, as a result of the final decisions in the US and UK, continues to be free to do so in the US and UK. INTELLiVENT-ASV is the result of decades of original research and innovation.

Contact

Hamilton Medical AG
Frieder Reusch
Intellectual Property Manager

freusch@hamilton.ch

 +49 (0) 89 248804027

www.hamilton-medical.com